KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Other financing activities (2017 - 2025)

Inovio Pharmaceuticals' Other financing activities history spans 8 years, with the latest figure at -$1787.0 for Q3 2025.

  • For Q3 2025, Other financing activities rose 72.16% year-over-year to -$1787.0; the TTM value through Sep 2025 reached -$110783.0, up 73.67%, while the annual FY2024 figure was -$420795.0, 9.83% up from the prior year.
  • Other financing activities for Q3 2025 was -$1787.0 at Inovio Pharmaceuticals, up from -$34777.0 in the prior quarter.
  • Across five years, Other financing activities topped out at -$1787.0 in Q3 2025 and bottomed at -$4.6 million in Q4 2021.
  • The 4-year median for Other financing activities is -$54498.0 (2025), against an average of -$560957.2.
  • The largest annual shift saw Other financing activities tumbled 643.62% in 2024 before it skyrocketed 85.52% in 2025.
  • A 4-year view of Other financing activities shows it stood at -$4.6 million in 2021, then surged by 99.79% to -$9650.0 in 2023, then skyrocketed by 33.49% to -$6418.0 in 2024, then skyrocketed by 72.16% to -$1787.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Other financing activities are -$1787.0 (Q3 2025), -$34777.0 (Q2 2025), and -$74219.0 (Q1 2025).